Novel Peptide Targets Both Appetite and Metabolism Through Combined MC4 and GLP-1 Receptor Activation | Research

The takeaway

A single peptide combining melanocortin-4 and GLP-1 receptor agonism showed improved weight loss and metabolic outcomes with better tolerability than GLP-1 alone in preclinical models.

Dual MC4 + GLP-1 agonism
Single peptide targets two pathways for enhanced weight loss with improved tolerability

What the researchers found

A monomeric peptide combining MC4 and GLP-1 receptor agonism showed enhanced weight loss and metabolic benefits with improved tolerability in preclinical models.

Why it matters

Better-tolerated obesity drugs are urgently needed, especially for children and adolescents. Dual MC4/GLP-1 targeting could provide a new pathway to effective, tolerable weight loss therapy.

How the study worked

Peptide design fusing α-MSH and Exendin-4 sequences, followed by in vitro receptor activation assays and in vivo metabolic studies in animal models.

What this study cannot tell us

Preclinical data only — animal models may not predict human efficacy or tolerability; single peptide design challenges for manufacturing and stability.

How to read the evidence

Preclinical animal study — promising proof-of-concept but years from potential clinical use.

When this study was published

Published 2026 in Metabolism.

The bigger picture

Beyond dual GIP/GLP-1 agonists (tirzepatide), multi-target peptides incorporating appetite-regulatory pathways like MC4 represent the next frontier in obesity pharmacotherapy.

Questions still open

Will the improved tolerability translate to human trials?
How does MC4/GLP-1 dual targeting compare to GIP/GLP-1 dual agonism?

Common questions

What is MC4 receptor targeting?

The melanocortin-4 receptor is a brain receptor that controls appetite and energy balance. Activating it reduces hunger. Combining MC4 targeting with GLP-1 activation may produce better weight loss with fewer GI side effects.

Could this replace current weight loss drugs?

It's too early to say — this is a promising preclinical finding. If it works in human trials, it could offer a better-tolerated alternative to current GLP-1-only approaches, particularly for younger patients.

Read the original research

A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.

Metabolism: clinical and experimental, 174, 156414

View on PubMed ↗Publisher’s paper ↗

Citation

Ashlaw, Emily F; Elfers, Clinton T; Chichura, Kylie S; Miranda, Isabella Chavez; McGivney, Aelish; Chepurny, Oleg G; Holz, George G; Mullins, Ginger; den Hartigh, Laura J; Liu, Yongjun; Roth, Christian L; Doyle, Robert P. (2026). A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.. Metabolism: clinical and experimental, 174, 156414. https://doi.org/10.1016/j.metabol.2025.156414